Harrow (NASDAQ:HROW) reaffirmed its full-year 2025 revenue guidance of $270 million to $280 million on Monday, signaling confidence in its growing branded portfolio despite a strategic exit from the California compounding market.
The Nashville-based eyecare specialist also unveiled an aggressive 2026 commercial expansion, including plans to double its sales force for its cornerstone dry-eye and surgical products.
The company is moving to capitalize on recent market access wins by doubling its VEVYE sales territories to approximately 100 by Memorial Day 2026.
This push follows the January 1 launch of expanded coverage with a major U.S. pharmacy benefit manager.
Simultaneously, Harrow intends to double its surgical sales force for TRIESENCE and pivot IHEEZO toward a broader, office-based procedure market that management estimates exceeds 2.5 million annual use cases.
Operational changes also accompanied the financial update, led by the promotion of Patrick W. Sullivan to Chief Commercial Officer and the launch of "OneHarrow," a unified branding initiative designed to consolidate its previously separate Harrow and ImprimisRx commercial teams.
The company also addressed legacy regulatory friction, announcing that its ImprimisRx subsidiary settled California Board of Pharmacy matters with a $157,000 fine and voluntarily ceased compounding operations in the state effective Feb. 1, 2026.